We believe by combining data and medical know-how, we can predict complications that lead to rapid health deterioration or death. Medopad and Tencent are conducting trials to develop and validate algorithms that can potentially predict complications across a range of disease indications like Parkinson’s, Cancer and Heart Diseases.
Medopad and Tencent have partnered to bring A.I. and predictive analytics to the world of medicine. One of the first joint projects is the development of an A.I. technology system to support Parkinson’s patients and their clinicians. The Markerless Motion Capture and Analysis System (MMCAS) provides a highly accurate, real-time assessment of facial features and joint movements, identifying the frequency, range, and intensity of movement. The system is currently under clinical trial evaluation. We are working on a pipeline of exciting AI projects and will share more detail in upcoming months.